ERT eClinical Solutions Support 75% of 2019 FDA Approvals

▤ Summary

ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced an ERT record: 75% of the compounds approved by U.S. FDA in 2019 were developed using one or more of ERT’s eClinical solutions during the drug development process. ERT delivers innovative imaging, cardiac safety, respiratory, and electronic Clinical Outcome Assessment (eCOA) solutions that help biopharmaceutical companies meet global regulators’ strict guidelines for demonstrating the safety and efficacy of new medical compounds. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards. Pharma companies, biotechs and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly - and with confidence.

▦ Linked Companies

ERT Clinical

$500M to $1B